Skip to content
‹ Back to IndustriesHealthcare

What Should Building Managers Do If COVID Doesn’t Go Away?

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year. There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
What Should Building Managers Do If COVID Doesn’t Go Away?

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year.

There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the vaccine isn’t effective, the virus mutates or it returns in different forms, like the flu?

Those possibilities are why everyone, but especially building managers, must ask the question of what we do if COVID doesn’t go away, said John Shanahan, President of Ionogen.

“Maybe it’s a mutation or maybe the flu gets smarter. We have to have more long-term strategies for getting people back into business,” Shanahan said.

Shanahan has found his company’s hypochlorous solutions highly effective in Ionogen’s own office, with none of his team of 50 testing positive for COVID during the pandemic.

“In February, when this really started to ramp up, we deployed all the humidification devices in our building. Because we made surface sanitizers and disinfectants and they were still trying to figure out what COVID was, we put the air sanitizers up as a preventative measure,” he said. “We were so busy February, March, April and May that there was no stopping. But because we have both the physical staff in our manufacturing division and we needed to be able to collaborate, we just added more units into our space.”

Now, they’re looking into the positive results of hypochlorous actually getting into the upper respiratory areas and potentially killing the virus.

“We’re very excited about the future of where this is going to take us. We will continue, as always, to do more testing and trials and the continued research on this,” Shanahan said. “We’re committed to science, and we like proof. Anecdotes are great, and we’ve got a lot of anecdotes about how this has worked up until now. Now, we’ll continue to dig down into the science. Hypochlorous could very well be the antidote without having to take the immunization.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in Q3 2026 and raised 2026 revenue guidance to $1.04-$1.05 billion. Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a minimal residual disease assay, is targeted to launch before year-end.

  • 01Caris said higher operating expenses were driven primarily by headcount-related costs, research and development investment and marketing.
  • 02Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
  • 03Caris reaffirms its guidance for clinical therapy selection volume growth of approximately 20%.

Nov 8, 2026

Denials get a queue, underpayments just look like paid claims

Denials get a queue, underpayments just look like paid claims

Underpayments in healthcare revenue cycle operations lack the visibility of denied claims because they don't trigger alerts or queue workflows. Without dedicated ownership and line-level verification against contract terms, paid claims that fall short of their contractual amount pass through undetected.

  • 01Denial workflows activate on rejection events, but underpayments produce no event, leaving paid claims unverified by default.
  • 02The speaker says many provider groups lack line-level contract intelligence to check each paid line against the applicable terms.
  • 03Payment received and payment checked are separate tasks: one verifies acceptance, the other verifies correctness—and the second often has no assigned owner.

Nov 6, 2026

A zero-paid claim line is not automatically an underpayment

A zero-paid claim line is not automatically an underpayment

A zero payment on a claim line isn't automatically an underpayment; contract terms, particularly packaging rules, determine whether zero is correct. Chasing unsupported findings damages credibility with payers and weakens the position of legitimate disputes, so revenue cycle teams must verify the full contract terms and effective dates before treating any payment difference as a finding.

  • 01When a contract packages add-ons into the primary procedure, the add-on line may legitimately show zero payment because it is folded into the primary procedure reimbursement.
  • 02Pursuing payment differences that lack contract support burns credibility with payers and can weaken the team’s position on later disputes, including valid ones.
  • 03Always verify the complete contract terms, fee schedules, carve-outs, amendments, and the specific version in effect on the date of service before treating a payment variance as a recoverable underpayment.

Nov 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512